The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Swain, S. M., Whaley, F. S., & Ewer, M. S. (2003) · Cancer · doi:10.1002/cncr.11407 · Cited by 2,313
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G. J., Wei, J., & Nie, G. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.083 · Cited by 1,801
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Incidence and Mortality and Epidemiology of Breast Cancer in the World
Ghoncheh, M., Pournamdar, Z., & Salehiniya, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.s3.43 · Cited by 1,115
Nanotechnology: Intelligent Design to Treat Complex Disease
Couvreur, P., & Vauthier, C. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-0284-8 · Cited by 948
Bovine milk-derived exosomes for drug delivery
Munagala, R., Aqil, F., Jeyabalan, J., & Gupta, R. C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.020 · Cited by 931
Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program
Ibrahim, A. S., Khaled, H. M., Mikhail, N. N., Baraka, H., & Kamel, H. (2014) · Journal of Cancer Epidemiology · doi:10.1155/2014/437971 · Cited by 901
Clinical Applications of Magnetic Drug Targeting
Lübbe, A. S., Alexiou, C., & Bergemann, C. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2000.6030 · Cited by 844
Doxorubicin-Induced Cardiomyopathy
Takemura, G., & Fujiwara, H. (2007) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2006.10.002 · Cited by 827
Lipshultz, S. E., Lipsitz, S. R., Mone, S. M., Goorin, A. M., Sallan, S. E., Sanders, S. P., Orav, E. J., Gelber, R. D., & Colan, S. D. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322602 · Cited by 803
Johannsen, M., Gneveckow, U., Eckelt, L., Feussner, A., WaldÖFner, N., Scholz, R., Deger, S., Wust, P., Loening, S. A., & Jordan, A. (2005) · International Journal of Hyperthermia · doi:10.1080/02656730500158360 · Cited by 798
Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., Holmström, A., Chang, A. C., Coronado, M. J., Ebert, A. D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4087 · Cited by 742
Vasey, P. A., Kaye, S. B., Morrison, R. A., Twelves, C. J., Wilson, P., Duncan, R., Thomson, A. H., Murray, L. S., Hilditch, T. E., Murray, T., et al. (1999) · PubMed · Cited by 689
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Chitosan Nanoparticles: A Promising System in Novel Drug Delivery
Nagpal, K., Singh, S. K., & Mishra, D. N. (2010) · CHEMICAL & PHARMACEUTICAL BULLETIN · doi:10.1248/cpb.58.1423 · Cited by 660
Current Trends in The Use of Liposomes for Tumor Targeting
Deshpande, P. P., Biswas, S., & Torchilin, V. P. (2013) · Nanomedicine · doi:10.2217/nnm.13.118 · Cited by 657
Prognostic and Predictive Factors in Early-Stage Breast Cancer
Cianfrocca, M., & Goldstein, L. J. (2004) · The Oncologist · doi:10.1634/theoncologist.9-6-606 · Cited by 637
Pluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623
The anthracyclines: will we ever find a better doxorubicin?
Weiss, R. B. (1992) · PubMed · Cited by 558
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5391 · Cited by 538
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., Vonhof, S., Bickeböller, H., Toliat, M. R., Suk, E.-K., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.576850 · Cited by 489
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., Costa, A., Winer, E. P., Cardoso, F., & on behalf of the ESO-MBC Task Force (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq029 · Cited by 422
Danson, S., Ferry, D., Alakhov, V, Margison, J., Kerr, D., Jowle, D., Brampton, M., Halbert, G., & Ranson, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601856 · Cited by 382
New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics
Tokarska-Schlattner, M., Zaugg, M., Zuppinger, C., Wallimann, T., & Schlattner, U. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2006.06.009 · Cited by 350
Torchilin, V. P. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.031 · Cited by 332
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
Caggiano, V., Weiss, R. V., Rickert, T. S., & Linde‐Zwirble, W. T. (2005) · Cancer · doi:10.1002/cncr.20983 · Cited by 328
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
Exosomes Increase the Therapeutic Index of Doxorubicin in Breast and Ovarian Cancer Mouse Models
Hadla, M., Palazzolo, S., Corona, G., Caligiuri, I., Canzonieri, V., Toffoli, G., & Rizzolio, F. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0154 · Cited by 282
Targeted and controlled anticancer drug delivery and release with magnetoelectric nanoparticles
Rodzinski, A., Guduru, R., Liang, P., Hadjikhani, A., Stewart, T., Stimphil, E., Runowicz, C., Cote, R., Altman, N., Datar, R., et al. (2016) · Scientific Reports · doi:10.1038/srep20867 · Cited by 271
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)
Lorusso, D., Di Stefano, A., Carone, V., Fagotti, A., Pisconti, S., & Scambia, G. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl477 · Cited by 265
Kareva, I., Waxman, D. J., & Lakka Klement, G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.12.039 · Cited by 249
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
Batrakova, E. V., Li, S., Elmquist, W. F., Miller, D. W., Alakhov, V. Y., & Kabanov, A. V. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2165 · Cited by 229
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
Symon, Z., Peyser, A., Tzemach, D., Lyass, O., Sucher, E., Shezen, E., & Gabizon, A. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990701)86:1<72::aid-cncr12>3.0.co;2-1 · Cited by 213
Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent Cancer
Vicent, M. J., Greco, F., Nicholson, R. I., Paul, A., Griffiths, P. C., & Duncan, R. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200462960 · Cited by 199
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
Lao, J., Madani, J., Puértolas, T., Álvarez, M., Hernández, A., Pazo-Cid, R., Artal, Á., & Antón Torres, A. (2013) · Journal of Drug Delivery · doi:10.1155/2013/456409 · Cited by 185
Cao, N., & Feng, S.-S. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.05.016 · Cited by 179
Multidrug resistance ABC transporters
Chang, G. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01085-8 · Cited by 177
Johnson, K. R., Ringland, C., Stokes, B. J., Anthony, D. M., Freemantle, N., Irs, A., Hill, S. R., & Ward, R. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70800-2 · Cited by 175
Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin
Zhang, J., Chen, X. G., Li, Y. Y., & Liu, C. S. (2007) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2007.08.002 · Cited by 171
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 167
Xing, M., Yan, F., Yu, S., & Shen, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133569 · Cited by 157
Exosomal Doxorubicin Reduces the Cardiac Toxicity of Doxorubicin
Toffoli, G., Hadla, M., Corona, G., Caligiuri, I., Palazzolo, S., Semeraro, S., Gamini, A., Canzonieri, V., & Rizzolio, F. (2015) · Nanomedicine · doi:10.2217/nnm.15.118 · Cited by 156
Novel method of doxorubicin–SPION reversible association for magnetic drug targeting
Munnier, E., Cohen-Jonathan, S., Linassier, C., Douziech-Eyrolles, L., Marchais, H., Soucé, M., Hervé-Aubert, K., Dubois, P., & Chourpa, I. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.006 · Cited by 152
Tsukioka, Y., Matsumura, Y., Hamaguchi, T., 小池浩代, Moriyasu, F., & Kakizoe, T. (2002) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2002.tb01217.x · Cited by 123
Sparano, J. A., Makhson, A. N., Семиглазов, В. Ф., Tjulandin, S., Balashova, O. I., Bondarenko, I., Bogdanova, N. V., Manikhas, G. M., Oliynychenko, G. P., Chatikhine, V. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5013 · Cited by 116
A pharmaceutical study of doxorubicin-loaded PEGylated nanoparticles for magnetic drug targeting
Gautier, J., Munnier, E., Paillard, A., Hervé-Aubert, K., Douziech-Eyrolles, L., Soucé, M., Dubois, P., & Chourpa, I. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.06.010 · Cited by 112
Abbasi, S. Q., Paul, A., Shao, W., & Prakash, S. (2011) · Journal of Drug Delivery · doi:10.1155/2012/686108 · Cited by 99
Sun, Y. P., & Wan, A. (2007) · Journal of Applied Polymer Science · doi:10.1002/app.26038 · Cited by 96
Yang, Y., Chen, Y., Zhang, F., Zhao, Q., & Zhong, H. (2015) · International Journal of Hyperthermia · doi:10.3109/02656736.2015.1036384 · Cited by 82
Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes
Gao, J., Zhong, W. H., He, J., Li, H., Zhang, H., Zhou, G., Li, B., Lü, Y., Zou, H. L., Kou, G., et al. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.03.018 · Cited by 80
Overcoming multidrug resistance with nanomedicines
Ganoth, A., Merimi, K. C., & Peer, D. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.960920 · Cited by 74
Al-Batran, S.-E., Bischoff, J., von Minckwitz, G., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603158 · Cited by 70
Guo, S., Lv, L., Shen, Y., Hu, Z., He, Q., & Chen, X. S. (2016) · Scientific Reports · doi:10.1038/srep21459 · Cited by 69
Al-Batran, S.-E., Meerpohl, H.-G., von Minckwitz, G., Atmaca, A., Kleeberg, U., Harbeck, N., Lerbs, W., Hecker, D., Sehouli, J., Knuth, A., et al. (2006) · Oncology · doi:10.1159/000093005 · Cited by 54
Nanoparticle Delivery Strategies to Target Doxorubicin to Tumor Cells and Reduce Side Effects
Wang, Y., Wei, X., Zhang, C., Zhang, F., & Liang, W. P. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.24 · Cited by 54
Guo, R., Zhang, L., Jiang, Z., Cao, Y., Ding, Y., & Jiang, X. (2007) · Biomacromolecules · doi:10.1021/bm060906i · Cited by 47
Schell, R. F., Sidone, B., Caron, W. P., Walsh, M. D., White, T. F., Zamboni, B. A., Ramanathan, R. K., & Zamboni, W. C. (2013) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2013.07.005 · Cited by 46
Fischer, J. R., Harkin, K. R., & Lc, F. (2002) · PubMed · Cited by 34
Irvin, W. J., Orlowski, R. Z., Chiu, W.-K., Carey, L., Collichio, F. A., Bernard, P. S., Stijleman, I. J., Perou, C. M., Ivanova, A., & Dees, E. C. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.n.061 · Cited by 32
Krishna, R., & Mayer, L. D. (2000) · PubMed · Cited by 28
Acid‐sensitive magnetic nanoparticles as potential drug depots
Wuang, S. C., Neoh, K. G., Kang, E. T., Leckband, D. E., & Pack, D. W. (2010) · AIChE Journal · doi:10.1002/aic.12373 · Cited by 26
Cited by
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Coenzyme Q10 Cardioprotective Effects Against Doxorubicin-Induced Cardiotoxicity in Wistar Rat
Botelho, A. F. M., Lempek, M. R., Branco, S. E. M. T., Nogueira, M. M., de Almeida, M. E., Costa, A. G., Freitas, T. G., Rocha, M. C. R. C., Moreira, M. V. L., Barreto, T. O., et al. (2020) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09547-4 · Cited by 45
Metadata
- Authors
- Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., & Ellithy, M.
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2017-11
- Volume
- 95
- Pages
- 1209-1218
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W2755778068
- Cited by
- 318
- References
- 72
- FWCI
- 6.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.